GIA
ALXN

Gateway Investment Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Gateway Investment Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,923
Closed -$353K – 540
2021
Q2 		$353K Sell
1,923
-51
-3% -$8.75K ﹤0.01% 461
2021
Q1 		$302K Sell
1,974
-55
-3% -$8.51K ﹤0.01% 473
2020
Q4 		$317K Sell
2,029
-117
-5% -$15K ﹤0.01% 466
2020
Q3 		$246K Sell
2,146
-144
-6% -$15.5K ﹤0.01% 482
2020
Q2 		$257K Sell
2,290
-718
-24% -$76.2K ﹤0.01% 479
2020
Q1 		$270K Buy
3,008
+261
+10% +$25.6K ﹤0.01% 464
2019
Q4 		$297K Sell
2,747
-398
-13% -$42.6K ﹤0.01% 492
2019
Q3 		$308K Sell
3,145
-6,257
-67% -$705K ﹤0.01% 506
2019
Q2 		$1.23M Sell
9,402
-364
-4% -$46.9K 0.01% 422
2019
Q1 		$1.32M Sell
9,766
-128,834
-93% -$16M 0.01% 410
2018
Q4 		$13.5M Buy
138,600
+490
+0.4% +$57.9K 0.13% 163
2018
Q3 		$19.2M Sell
138,110
-287
-0.2% -$36K 0.16% 140
2018
Q2 		$17.2M Sell
138,397
-3,432
-2% -$401K 0.15% 149
2018
Q1 		$15.8M Sell
141,829
-1,370
-1% -$164K 0.14% 158
2017
Q4 		$17.1M Buy
143,199
+2,861
+2% +$348K 0.15% 149
2017
Q3 		$19.7M Sell
140,338
-14,193
-9% -$1.93M 0.17% 138
2017
Q2 		$18.8M Buy
154,531
+13,978
+10% +$1.63M 0.17% 148
2017
Q1 		$17M Sell
140,553
-25,851
-16% -$3.33M 0.16% 154
2016
Q4 		$20.4M Sell
166,404
-2,223
-1% -$272K 0.19% 140
2016
Q3 		$20.7M Sell
168,627
-16,213
-9% -$2.09M 0.18% 144
2016
Q2 		$21.6M Buy
184,840
+23,032
+14% +$3.27M 0.19% 139
2016
Q1 		$22.5M Buy
161,808
+173
+0.1% +$25.4K 0.2% 136
2015
Q4 		$30.8M Sell
161,635
-6,767
-4% -$1.18M 0.26% 107
2015
Q3 		$26.3M Buy
168,402
+26,004
+18% +$4.74M 0.23% 112
2015
Q2 		$25.7M Sell
142,398
-114
-0.1% -$19.7K 0.21% 129
2015
Q1 		$24.7M Buy
142,512
+85
+0.1% +$15.4K 0.2% 134
2014
Q4 		$26.4M Buy
142,427
+18,837
+15% +$3.49M 0.22% 126
2014
Q3 		$20.5M Buy
123,590
+16,999
+16% +$2.79M 0.16% 146
2014
Q2 		$16.7M Buy
106,591
+34,350
+48% +$5.42M 0.13% 172
2014
Q1 		$11M Buy
72,241
+50,083
+226% +$7.96M 0.09% 203
2013
Q4 		$2.95M Sell
22,158
-927
-4% -$111K 0.02% 340
2013
Q3 		$2.68M Buy
23,085
+2,180
+10% +$239K 0.02% 346
2013
Q2 		$1.93M Buy
+20,905
New +$2.01M 0.02% 382

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Gateway Investment Advisers's ALXN Position: Q3 2021 in Review

Gateway Investment Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,923 shares — an estimated $353K sold.

Gateway Investment Advisers first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $30.8M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Gateway Investment Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Gateway Investment Advisers sold 1,923 Alexion Pharmaceuticals shares in Q3 2021, an estimated $353K.
  • Gateway Investment Advisers first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Gateway Investment Advisers's Alexion Pharmaceuticals position peaked at $30.8M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Gateway Investment Advisers's 13F filing for Q3 2021, filed 22 Oct 2021.